Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Daiichi Sankyo
Merus B.V.
Pfizer
Amgen
M.D. Anderson Cancer Center
Guangzhou University of Traditional Chinese Medicine
MacroGenics
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Celldex Therapeutics
Institut Paoli-Calmettes
Fudan University
Shanghai Minimally Invasive Surgery Center
Yixing People's Hospital
Xijing Hospital
Instituto do Cancer do Estado de São Paulo
Tianjin Medical University Cancer Institute and Hospital
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Xijing Hospital
Qilu Hospital of Shandong University
The Second Affiliated Hospital of Shandong First Medical University
Fudan University
Ruijin Hospital
Zhejiang Cancer Hospital
Chung-Ang University
Shanghai Changzheng Hospital
Ruijin Hospital
Ruijin Hospital
Wuhan University
Shanghai Zhongshan Hospital
West China Hospital
Huazhong University of Science and Technology
Sun Yat-sen University
Sun Yat-sen University
Shenzhen Hornetcorn Bio-technology Company, LTD
Zhejiang Cancer Hospital
Sun Yat-sen University
Soroka University Medical Center
FeRx